Black Swan Sale

50% Off Elite

Register Now!

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Last Close
Nov 21  •  04:00PM ET
27.25
Dollar change
+0.40
Percentage change
1.49
%
IndexRUT P/E- EPS (ttm)-2.69 Insider Own41.06% Shs Outstand47.65M Perf Week11.82%
Market Cap1.30B Forward P/E- EPS next Y-3.54 Insider Trans-0.45% Shs Float28.11M Perf Month4.05%
Enterprise Value797.51M PEG- EPS next Q-0.66 Inst Own68.38% Short Float6.87% Perf Quarter86.26%
Income-97.70M P/S- EPS this Y25.15% Inst Trans27.12% Short Ratio2.38 Perf Half Y151.85%
Sales0.00M P/B2.54 EPS next Y-25.08% ROA-22.55% Short Interest1.93M Perf YTD53.61%
Book/sh10.74 P/C2.53 EPS next 5Y-0.41% ROE-23.41% 52W High42.27 -35.53% Perf Year22.31%
Cash/sh10.77 P/FCF- EPS past 3/5Y-171.13% - ROIC-18.75% 52W Low6.43 323.79% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.87% 7.55% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin- ATR (14)1.95 Perf 10Y-
Dividend Ex-Date- Quick Ratio36.37 Sales Y/Y TTM- Profit Margin- RSI (14)56.61 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio36.37 EPS Q/Q-48.03% SMA203.72% Beta1.72 Target Price51.50
Payout- Debt/Eq0.02 Sales Q/Q- SMA503.02% Rel Volume0.58 Prev Close26.85
Employees69 LT Debt/Eq0.02 EarningsNov 06 BMO SMA20069.78% Avg Volume810.87K Price27.25
IPOJun 07, 2024 Option/ShortYes / Yes EPS/Sales Surpr.8.39% - Trades Volume468,379 Change1.49%
Date Action Analyst Rating Change Price Target Change
Nov-19-25Initiated BTIG Research Buy $47
Sep-16-25Initiated Truist Buy $44
Aug-06-25Initiated H.C. Wainwright Buy $31
Apr-08-25Initiated Citizens JMP Mkt Outperform
Jul-02-24Initiated TD Cowen Buy
Jul-02-24Initiated Stifel Buy $35
Jul-02-24Initiated Jefferies Buy $35
Nov-12-25 09:55AM
Nov-06-25 07:00AM
Nov-05-25 04:05PM
Sep-30-25 11:49AM
Sep-12-25 11:13AM
04:05PM Loading…
Sep-11-25 04:05PM
Sep-09-25 09:17PM
Sep-08-25 04:08PM
04:05PM
09:45AM
09:28AM
06:00AM
Sep-05-25 04:05PM
Aug-13-25 08:03AM
Aug-07-25 07:00AM
01:57PM Loading…
Jun-12-25 01:57PM
Jun-02-25 02:45PM
May-27-25 07:00AM
May-21-25 07:00AM
May-08-25 07:00AM
Apr-22-25 07:00AM
Mar-31-25 04:33AM
Mar-21-25 07:00AM
Mar-11-25 07:00AM
Mar-03-25 07:00AM
Feb-24-25 07:00AM
Jan-10-25 07:20AM
Jan-09-25 09:12AM
07:00AM
Dec-06-24 12:01PM
07:00AM Loading…
Nov-14-24 07:00AM
Nov-08-24 07:18AM
Nov-07-24 07:00AM
Nov-04-24 07:00AM
Sep-05-24 07:00AM
Aug-29-24 07:00AM
Aug-08-24 07:00AM
Aug-06-24 06:30AM
Jul-29-24 07:00AM
Jul-05-24 02:22PM
Jun-12-24 04:01PM
Jun-06-24 06:54PM
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ceesay AbrahamChief Executive OfficerNov 17 '25Sale25.195,833146,931573,746Nov 18 04:27 PM
Ceesay AbrahamChief Executive OfficerNov 17 '25Sale25.205,083128,11635,978Nov 18 04:27 PM
Bredt DavidChief Scientific OfficerNov 17 '25Sale25.198,500214,091401,142Nov 18 04:24 PM
Bredt DavidChief Scientific OfficerOct 15 '25Sale25.798,500219,196409,642Oct 16 04:30 PM
Ceesay AbrahamChief Executive OfficerOct 15 '25Sale25.815,833150,541579,579Oct 16 04:30 PM
Ceesay AbrahamChief Executive OfficerOct 15 '25Sale25.815,083131,18941,061Oct 16 04:30 PM
DAVID BREDTOfficerOct 15 '25Proposed Sale24.8825,500634,440Oct 15 04:26 PM
Ceesay AbrahamChief Executive OfficerSep 17 '25Sale26.3240,8351,074,725585,412Sep 19 04:05 PM
Ceesay AbrahamChief Executive OfficerSep 17 '25Sale26.3235,585936,47246,144Sep 19 04:05 PM
ABRAHAM CEESAYDirectorSep 17 '25Proposed Sale26.1952,5011,375,001Sep 17 04:28 PM
THE DOROTHY CEESAY IRREV TRUSTDirectorSep 17 '25Proposed Sale26.1945,7511,198,219Sep 17 04:26 PM
Bredt DavidChief Scientific OfficerSep 15 '25Sale24.198,500205,649418,142Sep 17 04:15 PM
Huber Reid MDirectorSep 12 '25Buy24.4820,400499,37420,400Sep 15 04:05 PM
PAUL STEVEN MDirectorSep 12 '25Buy24.6541,6661,027,11141,666Sep 15 04:05 PM
Young Wendy B.DirectorSep 11 '25Buy22.603,50079,1009,500Sep 11 06:13 PM
Gault CherylChief Operating OfficerSep 08 '25Option Exercise1.805,0009,000176,928Sep 10 04:15 PM
Gault CherylChief Operating OfficerSep 08 '25Sale38.335,000191,650171,928Sep 10 04:15 PM
CHERYL GAULTOfficerSep 08 '25Proposed Sale14.3610,000143,600Sep 08 04:24 PM
Bredt DavidChief Scientific OfficerAug 15 '25Sale15.008,500127,466426,642Aug 18 05:14 PM
Bredt DavidChief Scientific OfficerJul 15 '25Sale14.008,500118,962435,142Jul 16 04:14 PM
Bredt DavidChief Scientific OfficerJun 16 '25Sale11.008,50093,522443,642Jun 18 04:15 PM
DAVID BREDTOfficerJun 16 '25Proposed Sale11.1934,000380,460Jun 16 04:24 PM
Bredt DavidChief Scientific OfficerMay 15 '25Sale9.568,50081,262452,142May 19 04:30 PM
Bredt DavidChief Scientific OfficerApr 15 '25Sale9.578,50081,310460,642Apr 16 05:00 PM
Bredt DavidChief Scientific OfficerMar 14 '25Sale10.858,50092,205469,142Mar 17 05:00 PM
DAVID BREDTOfficerMar 14 '25Proposed Sale10.0225,500255,510Mar 14 04:20 PM
Ignelzi Troy A.Chief Financial OfficerMar 12 '25Buy10.109,90099,9909,900Mar 13 05:13 PM
Ignelzi Troy A.Chief Financial OfficerMar 13 '25Buy9.9810099810,000Mar 13 05:13 PM
Young Wendy B.DirectorMar 12 '25Buy10.216,00061,2506,000Mar 13 05:00 PM